Helicobacter pylori therapy: a paradigm shift

References

• Sugano K, Tack J, Kuipers EJ, et al. Kyoto global consensus report on Helicobacter pylori gastritis. Gut. 2015;64:1353–1367.
   PubMed Web of Science ®Google Scholar
• Graham DY. Helicobacter pylori update: gastric cancer, reliable therapy, and possible benefits. Gastroenterology. 2015;148:719–731.
   PubMed Web of Science ®Google Scholar
• Genta RM, Lew GM, Graham DY. Changes in gastric mucosa following eradication of Helicobacter pylori. Mod Pathol. 1993;6:281–289.
   PubMed Web of Science ®Google Scholar
• Sung JJ, Lin SR, Ching JY, et al. Atrophy and intestinal metaplasia one year after cure of H. pylori infection: a prospective, randomized study. Gastroenterology. 2000;119:7–14.
   PubMed Web of Science ®Google Scholar
• De Bernard M, Josenhans C. Pathogenesis of Helicobacter pylori infection. Helicobacter. 2014;19(Suppl 1):11–18.
   PubMed Web of Science ®Google Scholar
• Axon A. Helicobacter pylori and public health. Helicobacter. 2014;19(Suppl 1):68–73.
   PubMed Web of Science ®Google Scholar
• Sgouras DN, Trang TT, Yamaoka Y. Pathogenesis of Helicobacter pylori infection. Helicobacter. 2015;20(Suppl 1):8–16.
   PubMed Web of Science ®Google Scholar
• Geisler WM, Uniyal A, Lee JY, et al. Azithromycin versus doxycycline for urogenital Chlamydia trachomatis infection. N Engl J Med. 2015;373:2512–2521.
   PubMed Web of Science ®Google Scholar
• Ghanem KG, Erbelding EJ, Cheng WW, et al. Doxycycline compared with benzathine penicillin for the treatment of early syphilis. Clin Infect Dis. 2006;42:e45–e49.
   PubMed Web of Science ®Google Scholar
• Riedner G, Rusizoka M, Todd J, et al. Single-dose azithromycin versus penicillin G benzathine for the treatment of early syphilis. N Engl J Med. 2005;353:1236–1244.
   PubMed Web of Science ®Google Scholar
• Wu JY, Liou JM, Graham DY. Evidence-based recommendations for successful Helicobacter pylori treatment. Expert Rev Gastroenterol Hepatol. 2014;8:21–28.
   PubMed Web of Science ®Google Scholar
• Shiotani A, Cen P, Graham DY. Eradication of gastric cancer is now both possible and practical. Semin Cancer Biol. 2013;23:492–501.
   PubMed Web of Science ®Google Scholar
• Suerbaum S, Michetti P. Helicobacter pylori infection. N Engl J Med. 2002;347:1175–1186.
   PubMed Web of Science ®Google Scholar
• Graham DY, Shiotani A. New concepts of resistance in the treatment of Helicobacter pylori infections. Nat Clin Pract Gastroenterol Hepatol. 2008;5:321–331.
   PubMedGoogle Scholar
• Graham DY. Antibiotic resistance in Helicobacter pylori: implications for therapy. Gastroenterology. 1998;115:1272–1277.
   PubMed Web of Science ®Google Scholar
• Yonezawa H, Osaki T, Kamiya S. Biofilm Formation by Helicobacter pylori and its involvement for antibiotic resistance. Biomed Res Int. 2015;2015:914791.
   PubMed Web of Science ®Google Scholar
• Dore MP, Lu H, Graham DY. Role of bismuth in improving Helicobacter pylori eradication with triple therapy. Gut. 2016;65:870–878.
   Web of Science ®Google Scholar
• Graham DY. Helicobacter pylori eradication therapy research: ethical issues and description of results. Clin Gastroenterol Hepatol. 2010;8:1032–1036.
   PubMed Web of Science ®Google Scholar
• Graham DY. Editorial - avoiding unethical Helicobacter pylori clinical trials: susceptibility-based studies and probiotics as adjuvants. Helicobacter. 2015;20:321–325.
   PubMed Web of Science ®Google Scholar
• Goodwin CS, Worsley BW. Microbiology of Helicobacter pylori. Gastroenterol Clin North Am. 1993;22:5–19.
   PubMed Web of Science ®Google Scholar
• Borsch GM, Graham DY. Helicobacter pylori. In: Collen MJ, Benjamin SB, editors. Pharmacology of peptic ulcer disease (Handbook of experimental pharmacology). Vol. 99. Berlin: Springer; 1991. p. 107–148.
   Google Scholar
• Buzas GM, Jozan J. First-line eradication of H pylori infection in Europe: a meta-analysis based on congress abstracts, 1997–2004. World J Gastroenterol. 2006;12:5311–5319.
   PubMed Web of Science ®Google Scholar
• Graham DY, Fischbach L. Helicobacter pylori treatment in the era of increasing antibiotic resistance. Gut. 2010;59:1143–1153.
   PubMed Web of Science ®Google Scholar
• Yamaoka Y, Graham DY, Lu H. Should triple therapy for Helicobacter pylori infection be abandoned as no longer effective? US Gastroenterology. 2008;4:65–67.
   Google Scholar
• Graham DY, Lu H, Yamaoka Y. A report card to grade Helicobacter pylori therapy. Helicobacter. 2007;12:275–278.
   PubMed Web of Science ®Google Scholar
• Bochenek WJ, Peters S, Fraga PD, et al. Eradication of Helicobacter pylori by 7-day triple-therapy regimens combining pantoprazole with clarithromycin, metronidazole, or amoxicillin in patients with peptic ulcer disease: results of two double-blind, randomized studies. Helicobacter. 2003;8:626–642.
   PubMed Web of Science ®Google Scholar
• Fennerty MB, Kovacs TO, Krause R, et al. A comparison of 10 and 14 days of lansoprazole triple therapy for eradication of Helicobacter pylori. Arch Intern Med. 1998;158:1651–1656.
   PubMedGoogle Scholar
• Vakil N, Lanza F, Schwartz H, et al. Seven-day therapy for Helicobacter pylori in the United States. Aliment Pharmacol Ther. 2004;20:99–107.
   PubMed Web of Science ®Google Scholar
• Laine L, Frantz JE, Baker A, et al. A United States multicentre trial of dual and proton pump inhibitor-based triple therapies for Helicobacter pylori. Aliment Pharmacol Ther. 1997;11:913–917.
   PubMed Web of Science ®Google Scholar
• Zullo A, Vaira D, Vakil N, et al. High eradication rates of Helicobacter pylori with a new sequential treatment. Aliment Pharmacol Ther. 2003;17:719–726.
   PubMed Web of Science ®Google Scholar
• Vaira D, Zullo A, Vakil N, et al. Sequential therapy versus standard triple-drug therapy for Helicobacter pylori eradication: a randomized trial. Ann Intern Med. 2007;146:556–563.
   PubMed Web of Science ®Google Scholar
• Gatta L, Vakil N, Vaira D, et al. Global eradication rates for Helicobacter pylori infection: systematic review and meta-analysis of sequential therapy. BMJ. 2013;347:f4587.
   PubMed Web of Science ®Google Scholar
• Graham DY, Lee YC, Wu MS. Rational Helicobacter pylori therapy: evidence-based medicine rather than medicine-based evidence. Clin Gastroenterol Hepatol. 2014;12:177–186.
   PubMed Web of Science ®Google Scholar
• Shapiro S. Meta-analysis/Shmeta-analysis. Am J Epidemiol. 1994;140:771–778.
   PubMed Web of Science ®Google Scholar
• Graham DY, Dore MP. Helicobacter pylori therapy demystified. Helicobacter. 2011;16:343–345.
   PubMed Web of Science ®Google Scholar
• Gatta L, Vakil N, Leandro G, et al. Sequential therapy or triple therapy for Helicobacter pylori infection: systematic review and meta-analysis of randomized controlled trials in adults and children. Am J Gastroenterol. 2009;104:3069–3079.
   PubMed Web of Science ®Google Scholar
• Gisbert JP, Morena F. Systematic review and meta-analysis: levofloxacin-based rescue regimens after Helicobacter pylori treatment failure. Aliment Pharmacol Ther. 2006;23:35–44.
   PubMed Web of Science ®Google Scholar
• Liou JM, Chen CC, Chen MJ, et al. Sequential versus triple therapy for the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomized trial. Lancet. 2013;381:205–213.
   PubMed Web of Science ®Google Scholar
• Mégraud F, Bénéjat L, Ontsira Ngoyi EN, et al. Molecular approaches to identify Helicobacter pylori antimicrobial resistance. Gastroenterol Clin North Am. 2015;44:577–596.
   PubMed Web of Science ®Google Scholar
• Cosme A, Montes M, Martos M, et al. Usefulness of antimicrobial susceptibility in the eradication of Helicobacter pylori. Clin Microbiol Infect. 2013;19:379–383.
   PubMed Web of Science ®Google Scholar
• Graham DY, Kudo M, Reddy R, et al. Practical rapid, minimally invasive, reliable nonendoscopic method to obtain Helicobacter pylori for culture. Helicobacter. 2005;10:1–3.
   PubMed Web of Science ®Google Scholar
• Perez-Trallero E, Montes M, Alcorta M, et al. Non-endoscopic method to obtain Helicobacter pylori for culture. Lancet. 1995;345:622–623.
   PubMed Web of Science ®Google Scholar
• Han SW, Flamm R, Hachem CY, et al. Transport and storage of Helicobacter pylori from gastric mucosal biopsies and clinical isolates. Eur J Clin Microbiol Infect Dis. 1995;14:349–352.
   PubMed Web of Science ®Google Scholar
• Graham DY. Hp-normogram (normo-graham) for assessing the outcome of H. pylori therapy: effect of resistance, duration, and CYP2C19 genotype. Helicobacter. 2016;21:85–90.
   PubMed Web of Science ®Google Scholar
• Borody TJ, Cole P, Noonan S, et al. Recurrence of duodenal ulcer and Campylobacter pylori infection after eradication. Med J Aust. 1989;151:431–435.
   PubMed Web of Science ®Google Scholar
• Graham DY, Lee S-Y. How to effectively use bismuth quadruple therapy: the good, the bad, and the ugly. Gastroenterol Clin North Am. 2015;44:537–563.
   PubMed Web of Science ®Google Scholar
• Zhang W, Chen Q, Liang X, et al. Bismuth, lansoprazole, amoxicillin and metronidazole or clarithromycin as first-line Helicobacter pylori therapy. Gut. 2015;64:1715–1720.
   PubMed Web of Science ®Google Scholar
• Borody TJ, George LL, Brandl S, et al. Helicobacter pylori eradication with doxycycline-metronidazole-bismuth subcitrate triple therapy. Scand J Gastroenterol. 1992;27:281–284.
   PubMed Web of Science ®Google Scholar
• Ciccaglione A, Cellini L, Grossi L, et al. A triple and quadruple therapy with doxycycline and bismuth for first-line treatment of Helicobacter pylori infection: a pilot study. Helicobacter. 2015;20:390–396.
   PubMed Web of Science ®Google Scholar
• Lu H, Zhang W, Graham DY. Bismuth-containing quadruple therapy for Helicobacter pylori: lessons from China. Eur J Gastroenterol Hepatol. 2013;25:1134–1140.
   PubMed Web of Science ®Google Scholar
• Graham DY, Lu H. Furazolidone in Helicobacter pylori therapy: misunderstood and often unfairly maligned drug told in a story of French bread. Saudi J Gastroenterol. 2012;18:1–2.
   PubMed Web of Science ®Google Scholar
• Gisbert JP, Castro-Fernandez M, Perez-Aisa A, et al. Fourth-line rescue therapy with rifabutin in patients with three Helicobacter pylori eradication failures. Aliment Pharmacol Ther. 2012;35:941–947.
   PubMed Web of Science ®Google Scholar
• Gisbert JP, Calvet X. Review article: rifabutin in the treatment of refractory Helicobacter pylori infection. Aliment Pharmacol Ther. 2012;35:209–221.
   PubMed Web of Science ®Google Scholar
• Borody TJ, Pang G, Wettstein AR, et al. Efficacy and safety of rifabutin-containing ‘rescue therapy’ for resistant Helicobacter pylori infection. Aliment Pharmacol Ther. 2006;23:481–488.
   PubMed Web of Science ®Google Scholar
• Lim HC, Lee YJ, An B, et al. Rifabutin-based high-dose proton-pump inhibitor and amoxicillin triple regimen as the rescue treatment for Helicobacter pylori. Helicobacter. 2014;19:455–461.
   PubMed Web of Science ®Google Scholar
• Ciccaglione AF, Tavani R, Grossi L, et al. Rifabutin containing triple therapy and rifabutin with bismuth containing quadruple therapy for third-line treatment of Helicobacter pylori infection: two pilot studies. Helicobacter. Forthcoming 2016.
   PubMed Web of Science ®Google Scholar
• Julapalli VR, Graham DY. Appropriate use of intravenous proton pump inhibitors in the management of bleeding peptic ulcer. Dig Dis Sci. 2005;50:1185–1193.
   PubMed Web of Science ®Google Scholar
• Scott D, Weeks D, Melchers K, et al. The life and death of Helicobacter pylori. Gut. 1998;43(Suppl 1):S56–S60.
   PubMed Web of Science ®Google Scholar
• Furuta T, Graham DY. Pharmacologic aspects of eradication therapy for Helicobacter pylori Infection. Gastroenterol Clin North Am. 2010;39:465–480.
   PubMed Web of Science ®Google Scholar
• Sakurai Y, Nishimura A, Kennedy G, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of single rising TAK-438 (Vonoprazan) doses in healthy male Japanese/non-Japanese subjects. Clin Transl Gastroenterol. 2015;6:e94.
   PubMed Web of Science ®Google Scholar
• Murakami K, Sakurai Y, Shiino M, et al. Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: a phase III, randomised, double-blind study. Gut. Forthcoming 2016.
   PubMed Web of Science ®Google Scholar